000275906 001__ 275906
000275906 005__ 20250126000515.0
000275906 0247_ $$2doi$$a10.1055/a-2370-1933
000275906 0247_ $$2pmid$$apmid:39384316
000275906 0247_ $$2ISSN$$a0303-4259
000275906 0247_ $$2ISSN$$a1439-0876
000275906 0247_ $$2altmetric$$aaltmetric:169248782
000275906 037__ $$aDZNE-2025-00139
000275906 041__ $$aGerman
000275906 082__ $$a610
000275906 1001_ $$aBohlken, Jens$$b0
000275906 245__ $$aAlzheimer-Demenz und Antidementiva-Verordnungen 2010–2021 in 357 Hausarzt- und 71 Facharztpraxen | Alzheimer's Dementia and Anti-Dementia Medication Prescriptions 2010-2021 in 357 GP Practices and 71 Specialist Practices
000275906 260__ $$aStuttgart$$bThieme$$c2025
000275906 3367_ $$2DRIVER$$aarticle
000275906 3367_ $$2DataCite$$aOutput Types/Journal article
000275906 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737366494_4997
000275906 3367_ $$2BibTeX$$aARTICLE
000275906 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275906 3367_ $$00$$2EndNote$$aJournal Article
000275906 520__ $$aThe predicted prevalence of people with dementia (PWD) in Germany has risen to 1.8 million since 2010. In the near future, we will see the approval of antibody therapies. The study aims to demonstrate the recent anti-dementia medication prescriptions and diagnosis prevalence.Data from 357 general practitioner (GP) and 71 specialist practices (SP) (1.1 Mio. patients) were analyzed to demonstrate the prevalence of dementia diagnoses and anti-dementia drug prescriptions between 2010 and 2021.The diagnosis prevalence of PWD (Alzheimer's dementia) remained relatively constant in GP practices at 1.0-1.3% (0.19-0.21%). Among SP, the prevalence increased from 4.9% (2.8%) to 5.9% (3.6%). The anti-dementia prescription rate decreased in GP (from 0.14% to 0.10%) and increased in SP practices (from 2.1% to 2.4%).The diagnosis and prescription rate, especially in GP practices, remained below the prevalence forecasts and the expected prescriptions.
000275906 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000275906 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275906 650_7 $$2NLM Chemicals$$aNootropic Agents
000275906 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000275906 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000275906 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000275906 650_2 $$2MeSH$$aHumans
000275906 650_2 $$2MeSH$$aGermany
000275906 650_2 $$2MeSH$$aAged
000275906 650_2 $$2MeSH$$aGeneral Practice: statistics & numerical data
000275906 650_2 $$2MeSH$$aMale
000275906 650_2 $$2MeSH$$aFemale
000275906 650_2 $$2MeSH$$aAged, 80 and over
000275906 650_2 $$2MeSH$$aPractice Patterns, Physicians': statistics & numerical data
000275906 650_2 $$2MeSH$$aForecasting
000275906 650_2 $$2MeSH$$aDrug Prescriptions: statistics & numerical data
000275906 650_2 $$2MeSH$$aCross-Sectional Studies
000275906 650_2 $$2MeSH$$aDementia: drug therapy
000275906 650_2 $$2MeSH$$aDementia: epidemiology
000275906 650_2 $$2MeSH$$aNootropic Agents: therapeutic use
000275906 7001_ $$aKostev, Karel$$b1
000275906 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b2$$eLast author$$udzne
000275906 773__ $$0PERI:(DE-600)2056552-5$$a10.1055/a-2370-1933$$gVol. 52, no. 1, p. 44 - 47$$n1$$p44 - 47$$tPsychiatrische Praxis$$v52$$x0303-4259$$y2025
000275906 909CO $$ooai:pub.dzne.de:275906$$pVDB
000275906 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000275906 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000275906 9141_ $$y2025
000275906 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPSYCHIAT PRAX : 2022$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2024-12-19
000275906 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-19
000275906 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000275906 980__ $$ajournal
000275906 980__ $$aVDB
000275906 980__ $$aI:(DE-2719)5000067
000275906 980__ $$aUNRESTRICTED